Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial

JCI insight

Volumn 3, Issue 5, 2018, Pages

  Francois, Bruno ^a,b,c   Jeannet, Robin ^b   Daix, Thomas ^a,b   Walton, Andrew H ^d   Shotwell, Matthew S ^e   Unsinger, Jacqueline ^d   Monneret, Guillaume ^f,g   Rimmelé, Thomas ^f,g   Blood, Teresa ^d   Morre, Michel ^h   Gregoire, Anne ^h   Mayo, Gail A ^e   Blood, Jane ^d   Durum, Scott K ⁱ   Sherwood, Edward R ^e,j   Hotchkiss, Richard S ^d,h  

^a Intensive Care Unit

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c UMR 1092   (France)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g UNIVERSITÉ LYON 1   (France)

^h Vanderbilt University Medical Center ^*

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Immunology; T cells

Indexed keywords

IL7 PROTEIN, HUMAN; INTERLEUKIN 7; RECOMBINANT PROTEIN;

ADULT; AGED; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 85049196343     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.98960     Document Type: Article

References (0)